RXi Pharmaceuticals reports Q1 earnings, highlights

WORCESTER, Mass. RXi Pharmaceuticals Corp., a biotech company developing drugs based on RNA interference, cited the publication of its in-licensed oral delivery technology in the journal Nature and the award of a grant from the Massachusetts Life Science Center to further support its research as highlights in its first-quarter 2009 financial report Friday.

RXi also said its research team had hade “dramatic breakthroughs” with its self-delivering rxRNA compounds.

The company reported a net loss of $4.2 million for the quarter, compared with  $2.6 million in first quarter 2008.